Foulkes et al. observed that TNBC which also expresses CK5/6, EGFR, or both may have a worse outcome than the TNBCs that are negative for both of these markers and the overexpression of EGFR is more common in the TNBCs than in other subtypes of breast cancer, and cetuximab, which is targeted against EGFR, is being further studied in combination with carboplatin [12]. This evidence concerns the gene EGFR and breast cancer.